Article

Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor

2020-10-30

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>EGFR tyrosine kinase inhibitors (TKIs) have been developed for the treatment of EGFR mutated NSCLC. Parthenolide, a natural product of parthenolide, which belongs to the sesquiterpene lactone family and has a variety of biological and therapeutic activities, including anti-cancer effects. However, its effect on non-small cell lung cancer is little known. <bold>M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b596bef7-eb84-590d-9a82-0928e1f7fce3
DOI: 10.21203/rs.3.rs-47249/v3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptorDOI 10.21203/rs.3.rs-47249/v3Read

Progress in Research on the Role of Flavonoids in Lung CancerSemantic proximity Read

Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancerSemantic proximity Read

Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.Semantic proximity Read

Antineoplastic Effects of Erufosine on Small and Non-Small Lung Cancer Cells Through Induction of Apoptosis and Cell Cycle ArrestSemantic proximity Read

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanismsSemantic proximity Read

Exploring acenocoumarol and silodosin as allosteric EGFR inhibitors for the treatment of non-small cell lung cancerSemantic proximity Read

Exploring the Efficacy of a Novel Cannabidiol and Bevacizumab Combination in Non-Small Cell Lung CancerSemantic proximity Read

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.Semantic proximity Read

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.Semantic proximity Read

Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in Non-small-cell lung cancer cells: from the insight into the gene transcriptional levelSemantic proximity Read

Isorhapontigenin is a novel potential therapeutic agent for lung cancer： evidence from network pharmacology, bioinformatics, molecular docking and in vitro experimentsSemantic proximity Read

Combining network pharmacology and transcriptomics to validate and explore the efficacy and mechanism of Huayu Wan in treating non-small cell lung cancerSemantic proximity Read